Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Laforêt

Showing results (71-80 of 164) with videos related to

Pageof 17
Sort By:
Neurology|December 18, 2012
High risk of severe cardiac adverse events in patients with mitochondrial m.3243A>G mutationEdoardo Malfatti, Pascal Laforêt, Claude Jardel, et al.
Neuromuscular Disorders : NMD|June 7, 2008
Distal inflammatory myopathy: unusual presentation of polymyositis or new entity?Dalia Dimitri, Odile Dubourg, Thierry Maisonobe, et al.
Neuromuscular Disorders : NMD|September 29, 2020
Biallelic mutations in Tenascin-X cause classical-like Ehlers-Danlos syndrome with slowly progressive muscular weaknessMarion Brisset, Corinne Metay, Robert-Yves Carlier, et al.
Journal of Neuromuscular Diseases|June 10, 2017
Risk for Complications after Pacemaker or Cardioverter Defibrillator Implantations in Patients with Myotonic Dystrophy Type 1Maximilien Sochala, Karim Wahbi, Emmanuel Sorbets, et al.
Neuromuscular Disorders : NMD|March 8, 2016
Atrial flutter in myotonic dystrophy type 1: Patient characteristics and clinical outcomeKarim Wahbi, Frederic A Sebag, Nicolas Lellouche, et al.
European Journal of Neurology|November 28, 2023
Long-term prognosis of fatty-acid oxidation disorders in adults: Optimism despite the limited effective therapies availableAlice Rouyer, Céline Tard, Anne-Frédérique Dessein, et al.
European Journal of Neurology|December 20, 2021
Motor and respiratory decline in patients with late onset Pompe disease after cessation of enzyme replacement therapy during COVID-19 pandemicCéline Tard, Emmanuelle Salort-Campana, Maud Michaud, et al.
Neuromuscular Disorders : NMD|February 21, 2006
A new mutation in PRKAG2 gene causing hypertrophic cardiomyopathy with conduction system disease and muscular glycogenosisPascal Laforêt, Pascale Richard, Mina Ait Said, et al.
Journal of Neuromuscular Diseases|June 6, 2018
Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia GravisOcéane Landon-Cardinal, Diane Friedman, Marguerite Guiguet, et al.
Molecular Genetics and Metabolism|March 20, 2013
Exercise intolerance in Glycogen Storage Disease Type III: weakness or energy deficiency?Nicolai Preisler, Agnès Pradel, Edith Husu, et al.
Pageof 17

Showing results (71-80 of 164) with videos related to

Sort By:
Pageof 17
Neurology|December 18, 2012
High risk of severe cardiac adverse events in patients with mitochondrial m.3243A>G mutationEdoardo Malfatti, Pascal Laforêt, Claude Jardel, et al.
Neuromuscular Disorders : NMD|June 7, 2008
Distal inflammatory myopathy: unusual presentation of polymyositis or new entity?Dalia Dimitri, Odile Dubourg, Thierry Maisonobe, et al.
Neuromuscular Disorders : NMD|September 29, 2020
Biallelic mutations in Tenascin-X cause classical-like Ehlers-Danlos syndrome with slowly progressive muscular weaknessMarion Brisset, Corinne Metay, Robert-Yves Carlier, et al.
Journal of Neuromuscular Diseases|June 10, 2017
Risk for Complications after Pacemaker or Cardioverter Defibrillator Implantations in Patients with Myotonic Dystrophy Type 1Maximilien Sochala, Karim Wahbi, Emmanuel Sorbets, et al.
Neuromuscular Disorders : NMD|March 8, 2016
Atrial flutter in myotonic dystrophy type 1: Patient characteristics and clinical outcomeKarim Wahbi, Frederic A Sebag, Nicolas Lellouche, et al.
European Journal of Neurology|November 28, 2023
Long-term prognosis of fatty-acid oxidation disorders in adults: Optimism despite the limited effective therapies availableAlice Rouyer, Céline Tard, Anne-Frédérique Dessein, et al.
European Journal of Neurology|December 20, 2021
Motor and respiratory decline in patients with late onset Pompe disease after cessation of enzyme replacement therapy during COVID-19 pandemicCéline Tard, Emmanuelle Salort-Campana, Maud Michaud, et al.
Neuromuscular Disorders : NMD|February 21, 2006
A new mutation in PRKAG2 gene causing hypertrophic cardiomyopathy with conduction system disease and muscular glycogenosisPascal Laforêt, Pascale Richard, Mina Ait Said, et al.
Journal of Neuromuscular Diseases|June 6, 2018
Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia GravisOcéane Landon-Cardinal, Diane Friedman, Marguerite Guiguet, et al.
Molecular Genetics and Metabolism|March 20, 2013
Exercise intolerance in Glycogen Storage Disease Type III: weakness or energy deficiency?Nicolai Preisler, Agnès Pradel, Edith Husu, et al.
Pageof 17